Significantly, other top ranking hits from our screen, such as CDK10, FGFBP1 and EGFR, have also been implicated as being overexpressed or pro-tumorigenic in the context of breast cancer, lending robust utility for our genome-wide screen with AMPI-109 in identifying aggressive, cancer-related markers. This evidence concerns the gene FGFBP1 and breast cancer.